E Ghione1, N Bergsland1, M G Dwyer1,2, J Hagemeier1, D Jakimovski1, I Paunkoski1, D P Ramasamy1, D Silva3, E Carl1, D Hojnacki4, C Kolb4, B Weinstock-Guttman4, R Zivadinov5,2. 1. From the Department of Neurology (E.G., N.B., M.G.D., J.H., D.J., I.P., D.P.R., E.C., R.Z.), Buffalo Neuroimaging Analysis Center. 2. Center for Biomedical Imaging at Clinical Translational Research Center (M.G.D., R.Z.), State University of New York, Buffalo, New York. 3. Novartis Pharmaceuticals AG (D.S.), Basel, Switzerland. 4. Jacobs Comprehensive MS Treatment and Research Center (D.H., C.K., B.W.-G.), Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York. 5. From the Department of Neurology (E.G., N.B., M.G.D., J.H., D.J., I.P., D.P.R., E.C., R.Z.), Buffalo Neuroimaging Analysis Center rzivadinov@bnac.net.
Abstract
BACKGROUND AND PURPOSE: The assessment of brain atrophy in a clinical routine is not performed routinely in multiple sclerosis. Our aim was to determine the feasibility of brain atrophy measurement and its association with disability progression in patients with MS followed in a clinical routine for 5 years. MATERIALS AND METHODS: A total of 1815 subjects, 1514 with MS and 137 with clinically isolated syndrome and 164 healthy individuals, were collected retrospectively. Of 11,794 MR imaging brain scans included in the analysis, 8423 MRIs were performed on a 3T, and 3371 MRIs, on a 1.5T scanner. All patients underwent 3D T1WI and T2-FLAIR examinations at all time points of the study. Whole-brain volume changes were measured by percentage brain volume change/normalized brain volume change using SIENA/SIENAX on 3D T1WI and percentage lateral ventricle volume change using NeuroSTREAM on T2-FLAIR. RESULTS: Percentage brain volume change failed in 36.7% of the subjects; percentage normalized brain volume change, in 19.2%; and percentage lateral ventricle volume change, in 3.3% because of protocol changes, poor scan quality, artifacts, and anatomic variations. Annualized brain volume changes were significantly different between those with MS and healthy individuals for percentage brain volume change (P < .001), percentage normalized brain volume change (P = .002), and percentage lateral ventricle volume change (P = .01). In patients with MS, mixed-effects model analysis showed that disability progression was associated with a 21.9% annualized decrease in percentage brain volume change (P < .001) and normalized brain volume (P = .002) and a 33% increase in lateral ventricle volume (P = .004). CONCLUSIONS: All brain volume measures differentiated MS and healthy individuals and were associated with disability progression, but the lateral ventricle volume assessment was the most feasible.
BACKGROUND AND PURPOSE: The assessment of brain atrophy in a clinical routine is not performed routinely in multiple sclerosis. Our aim was to determine the feasibility of brain atrophy measurement and its association with disability progression in patients with MS followed in a clinical routine for 5 years. MATERIALS AND METHODS: A total of 1815 subjects, 1514 with MS and 137 with clinically isolated syndrome and 164 healthy individuals, were collected retrospectively. Of 11,794 MR imaging brain scans included in the analysis, 8423 MRIs were performed on a 3T, and 3371 MRIs, on a 1.5T scanner. All patients underwent 3D T1WI and T2-FLAIR examinations at all time points of the study. Whole-brain volume changes were measured by percentage brain volume change/normalized brain volume change using SIENA/SIENAX on 3D T1WI and percentage lateral ventricle volume change using NeuroSTREAM on T2-FLAIR. RESULTS: Percentage brain volume change failed in 36.7% of the subjects; percentage normalized brain volume change, in 19.2%; and percentage lateral ventricle volume change, in 3.3% because of protocol changes, poor scan quality, artifacts, and anatomic variations. Annualized brain volume changes were significantly different between those with MS and healthy individuals for percentage brain volume change (P < .001), percentage normalized brain volume change (P = .002), and percentage lateral ventricle volume change (P = .01). In patients with MS, mixed-effects model analysis showed that disability progression was associated with a 21.9% annualized decrease in percentage brain volume change (P < .001) and normalized brain volume (P = .002) and a 33% increase in lateral ventricle volume (P = .004). CONCLUSIONS: All brain volume measures differentiated MS and healthy individuals and were associated with disability progression, but the lateral ventricle volume assessment was the most feasible.
Authors: Stephen M Smith; Yongyue Zhang; Mark Jenkinson; Jacqueline Chen; P M Matthews; Antonio Federico; Nicola De Stefano Journal: Neuroimage Date: 2002-09 Impact factor: 6.556
Authors: N De Stefano; A Giorgio; M Battaglini; M Rovaris; M P Sormani; F Barkhof; T Korteweg; C Enzinger; F Fazekas; M Calabrese; D Dinacci; G Tedeschi; A Gass; X Montalban; A Rovira; A Thompson; G Comi; D H Miller; M Filippi Journal: Neurology Date: 2010-06-08 Impact factor: 9.910
Authors: Robert Zivadinov; Dejan Jakimovski; Sirin Gandhi; Rahil Ahmed; Michael G Dwyer; Dana Horakova; Bianca Weinstock-Guttman; Ralph R H Benedict; Manuela Vaneckova; Michael Barnett; Niels Bergsland Journal: Expert Rev Neurother Date: 2016-05-13 Impact factor: 4.618
Authors: R Zivadinov; A T Reder; M Filippi; A Minagar; O Stüve; H Lassmann; M K Racke; M G Dwyer; E M Frohman; O Khan Journal: Neurology Date: 2008-07-08 Impact factor: 9.910
Authors: Ernst-Wilhelm Radue; Till Sprenger; Laura Gaetano; Nicole Mueller-Lenke; Steve Cavalier; Karthinathan Thangavelu; Michael A Panzara; Jessica E Donaldson; Fiona M Woodward; Jens Wuerfel; Jerry S Wolinsky; Ludwig Kappos Journal: Neurol Neuroimmunol Neuroinflamm Date: 2017-08-09
Authors: Michael G Dwyer; Jesper Hagemeier; Niels Bergsland; Dana Horakova; Jonathan R Korn; Nasreen Khan; Tomas Uher; Jennie Medin; Diego Silva; Manuela Vaneckova; Eva Kubala Havrdova; Robert Zivadinov Journal: Neuroimage Clin Date: 2018-02-07 Impact factor: 4.881
Authors: C M Dalton; P A Brex; R Jenkins; N C Fox; K A Miszkiel; W R Crum; J I O'Riordan; G T Plant; A J Thompson; D H Miller Journal: J Neurol Neurosurg Psychiatry Date: 2002-08 Impact factor: 10.154
Authors: E Ghione; N Bergsland; M G Dwyer; J Hagemeier; D Jakimovski; D P Ramasamy; D Hojnacki; A A Lizarraga; C Kolb; S Eckert; B Weinstock-Guttman; R Zivadinov Journal: AJNR Am J Neuroradiol Date: 2020-08-06 Impact factor: 3.825